Background and objectives Increased arterial stiffness was reported to be associated with decreased estimated GFR (eGFR). Previous studies suggested that arterial stiffness might play a role in renal function progression in patients with chronic kidney disease (CKD). The aim of this study was to investigate whether there was an independent association between brachial-ankle pulse wave velocity (baPWV), a marker of arterial stiffness, and renal function progression in CKD patients.
Introduction
Chronic kidney disease (CKD) is an increasing worldwide public health problem associated with increased cardiovascular morbidity and mortality. The excess cardiovascular risk is contributed to traditional risk factors and nontraditional risk factors including arterial stiffening (1, 2) . Increased arterial stiffness may be responsible for cardiovascular burden in the CKD population (3, 4) . Previous studies have reported the association between decreased estimated GFR (eGFR) and increased arterial stiffness (5) (6) (7) . Decreased eGFR may predispose to increased arterial stiffness with multiple pathogenic mechanisms involved, including deranged calcium/phosphate balance, secondary hyperparathyroidism, homocysteine, lipoprotein(a) metabolism, fluid overload, alterations in the angiotensin and endothelin systems, malnutrition, uremic toxins, oxidative stress, insulin resistance, and alterations in inflammatory and coagulation pathways (8, 9) . Conversely, there is evidence to suggest that arterial stiffness may play a role in renal function progression.
Three studies have shown that different measures of arterial stiffness, i.e., augmentation index, radial-dorsalis pedis pulse wave velocity (PWV), and aortic PWV, were independent risk factors for the deterioration of renal function in CKD patients (10 -12) .
To assess arterial stiffness, many noninvasive methods have been developed, and they usually require expertise techniques (13) . A clinical device, ABI-form (VP1000; Colin Co. Ltd., Komaki, Japan), has been developed to automatically and simultaneously record pulse waves of the brachial and posterior tibial arteries, using an automated oscillometric method. Using this device, we can easily and automatically calculate the brachial-ankle PWV (baPWV) (14 -16) . The baPWV has been reported as a good marker for arterial stiffness (15) . Accordingly, the aim of this study is to investigate whether there is an independent association between baPWV and renal function decline and progression to commencement of dialysis or death in a cohort of patients with CKD stages 3 to 5.
Materials and Methods

Study Patients
The study was conducted in a regional hospital in southern Taiwan. We consecutively enrolled 179 patients with CKD stages 3 to 5 according to the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines (17) from our Outpatient Department of Internal Medicine from January 2007 to May 2007. We classified our patients with evidence of kidney damage lasting for Ͼ3 months into CKD stages 3, 4, and 5, based on eGFR level (ml/min per 1.73 m 2 ) of 30 to 59, 15 to 29, and Ͻ15, respectively. Six patients with atrial fibrillation, 4 patients with inadequate image visualization, and 13 patients with less than three eGFR measurements during the follow-up period were excluded. In addition, those patients with mortality (n ϭ 4) or entering dialysis therapy (6 hemodialysis and 1 peritoneal dialysis) within 30 days after enrollment were also excluded to avoid incomplete observation of change in renal function. Finally, 145 patients (mean age, 68.6 Ϯ 12.1 years; 99 men) were included in this study. The protocol was approved by our Institutional Review Board, and all enrolled patients gave written, informed consent.
Measurement of baPWV
The values of baPWV were measured using an ABI-form device (VP1000; Colin Co. Ltd.), which automatically and simultaneously record pulse waves of the brachial and posterior tibial arteries, using an automated oscillometric method (14 -16) . The baPWV measurements were taken in a room with a temperature of around 25°C after 5 minutes of rest in the supine position. For measuring baPWV, pulse waves obtained from the brachial and tibial arteries were recorded simultaneously, and the transmission time (⌬Tba), which was defined as the time interval between the initial increase in brachial and ankle waveforms, was determined ( Figure 1 ). The transmission distance from the brachium to ankle was calculated according to body height. The path length from the suprasternal notch to the brachium (Lb) was obtained using the following equation: Lb ϭ 0.2195 ϫ height of the patient (in cm) Ϫ 2.0734. The path length from the suprasternal notch to the ankle (La) was obtained using the following equation: La ϭ (0.8129 ϫ height of the patient [in cm] ϩ 12.328). Finally, the following equation was used to automatically obtain baPWV: baPWV ϭ (La Ϫ Lb)/⌬Tba (15) . After obtaining bilateral baPWV values, the higher one was used for analysis. Systolic and diastolic BP and heart rate were measured using an appropriate cuff size by the same device. The average of systolic and diastolic BP of bilateral arms was used for analysis. The baPWV measurement was done once in each patient. The validation of this automatic device and its reproducibility have been previously published (15) .
Collection of Demographic, Medical, and Laboratory Data
Demographic and medical data including age, gender, smoking history (ever versus never), and comorbid conditions were obtained from medical records and interviews with patients. Study subjects were defined as having diabetes mellitus (DM) if the fasting blood glucose level was Ͼ126 mg/dl or hypoglycemic agents were used to control blood glucose levels. Similarly, study patients were considered as having hypertension if the systolic BP was Ն140 mmHg or diastolic BP Ն90 mmHg or anti-hypertensive drugs were prescribed. Cerebrovascular disease was defined as a history of cerebrovascular accident including cerebral bleeding and infarction. Coronary artery disease was defined as a history of typical angina with positive stress test, old myocardial infarction, or having undergone coronary artery bypass surgery or angioplasty. The body mass index was calculated as the ratio of weight in kilograms divided by square of height in meters. Laboratory data were measured from fasting blood samples using an autoanalyzer (D-68298 Mannheim COBAS Integra 400; Roche Diagnostics GmbH). Serum creatinine was measured by the compensated Jaffé (kinetic alkaline picrate) method in a Roche/Integra 400 Analyzer (Roche Diagnostics, Mannheim, Germany) using a calibrator traceable to isotope-dilution mass spectrometry (18) . The value of eGFR was calculated using the four-variable equation in the Modification of Diet in Renal Disease study (19) . Serum intact parathyroid hormone (PTH) concentration was evaluated using a commercially available two-sided immunoradiometric assay (CIS Biointernational). Blood samples were obtained within 1 month of enrollment. Urine albumin and creatinine were measured on a spot urine sample by an autoanalyzer (COBAS Integra 400 plus; Roche Diagnostics), and albuminuria was defined as the ratio of urine albumin to creatinine of Ն30 mg/g. In addition, information regarding patient medications including aspirin, angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), ␤-blockers, calcium channel blockers, diuretics, HMG-CoA reductase inhibitors (statins), and erythropoiesis-stimulating agents (ESAs) during the study period was obtained from medical records. 
Assessment of Decline in Renal Function
The decline in renal function was assessed by the eGFR slope, defined as the regression coefficient between eGFR and time in units of ml/min per 1.73 m 2 per year. At least three eGFR measurements were required to estimate eGFR slope. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines suggest that eGFR is normally declined Ͻ1 ml/min per 1.73 m 2 per year from a level of 125 ml/min per 1.73 m 2 once adulthood is reached (18) . Any reduction Ն1 ml/min per 1.73 m 2 per year, i.e., slope more negative than or equal to Ϫ1 ml/min per 1.73 m 2 per year (Յ Ϫ1), was considered the progression of CKD; otherwise, it was considered nonprogressive (17, 20) .
Definition of Study Endpoints
The study endpoints were defined as commencement of dialysis or death. In patients reaching study endpoints, renal function data were censored at the start of renal replacement therapy or death. The other patients were followed until March 2009. The mean follow-up period was 14.9 Ϯ 3.2 months (range, 4.7 to 26.2 months).
Statistical Analyses
Statistical analysis was performed using SPSS version 12.0 (SPSS, Chicago, IL) for Windows. Data are expressed as percentages or mean Ϯ SD. The differences between groups were checked by 2 test for categorical variables or by independent t test for continuous variables. The relationship between two continuous variables was assessed by a bivariate correlation method (Pearson's correlation). Linear regression analysis was used to identify the factors associated with decline in kidney function. Because the formula of eGFR included age and thus simultaneous adjustments for the eGFR and age might produce confusing linearity within regression model, the parameter of age was not put in multivariate linear regression analysis. Time to combined endpoints of commencement of dialysis or death and covariates of risk factors were modeled using the Cox proportional hazards model. Age, gender, and the significant variables in univariate analysis were selected for multivariate analysis. The parameters of systolic BP, diastolic BP, and total cholesterol were not put in multivariate analysis to avoid potential colinearity. A difference was considered significant at P Ͻ 0.05.
The baPWV was partially dependent on BP (5), so it was adjusted for mean arterial pressure at the time of measurement before further analysis. Adjustment was performed by a linear regression of the two variables. The residual values were added to uncorrected baPWV to form the adjusted baPWV. Adjusted baPWV values were used for analysis.
Results
The clinical characteristics of study patients are shown in Table 1 . The values of eGFR slope and baPWV of all patients were Ϫ0.57 Ϯ 3.32 ml/min per 1.73 m 2 per year and 2055.3 Ϯ 920.5 cm/s, respectively. The average number of serum creatinine measurements during the follow-up period was 7.5 Ϯ 3.4 (range, 3 to 19). The underlying etiology of CKD in our patients included 69 with diabetic kidney disease (47.6%), 33 with nondiabetic glomerular diseases (22.8%), 28 with tubulointerstitial diseases (19.3%), 4 cases of hypertension (2.8%), and 11 caused by other diseases (7.6%).
The comparison of baseline characteristics between patients with progressive (Յ Ϫ1 ml/min per 1.73 m 2 per year) and nonprogressive (Ͼ Ϫ1 ml/min per 1.73 m 2 per year) eGFR slope (ml/min per 1.73 m 2 per year) are shown in Table 2 . Compared with patients with a nonprogressive eGFR slope, patients with a progressive eGFR slope had a lower percentage of male patients, higher prevalence of a history of DM, higher systolic BP, wider pulse pressure, higher heart rate, higher fasting glucose, higher triglyceride, lower LDL-cholesterol, lower hematocrit, lower baseline eGFR, higher phosphate, higher PTH level, higher prevalence of albuminuria, and higher baPWV level. In addition, patients in the progressive group had a lower percentage of having received ACEI and/or ARB therapy. Table 3 shows the determinants of eGFR slope in all patients. In the univariate analysis, eGFR slope had a significantly positive correlation with serum hematocrit, baseline eGFR, and calcium levels and negative correlation with DM and hypertension, heart rate, log triglyceride, phosphate, log PTH level, albuminuria, and baPWV. After multiple stepwise linear regression analysis, eGFR slope was correlated independently with hypertension (␤ ϭ Ϫ0.193, P ϭ 0.011), increased baseline eGFR (␤ ϭ 0.408, P Ͻ 0.001), and decreased baPWV (␤ ϭ Ϫ0.165, P ϭ 0.033). Figure 2 showed the regression plot between baPWV and eGFR slope. We further performed eGFR slope analysis using the three-variable Japanese equation (21) and found similar results, i.e., eGFR slope was significantly correlated with baseline eGFR (␤ ϭ 0.392, P Ͻ 0.001), hypertension (␤ ϭ Ϫ0.193, P ϭ 0.011), and baPWV (␤ ϭ Ϫ0.165, P ϭ 0.035).
The mean follow-up period was 14.9 Ϯ 3.2 months. During the period of follow-up, 17 patients started hemodialysis and 8 patients died, including fatal cardiovascular events (n ϭ 4), infectious disease (n ϭ 3), and gastrointestinal bleeding (n ϭ 1). The comparison of characteristics between patients who did and did not reach the study endpoints is shown in Table 4 . Compared with patients who did not reach the study endpoints, patients who reached the study endpoints were significantly associated with higher prevalence of a history of DM, cerebrovascular disease, and albuminuria, higher systolic BP, higher pulse pressure, lower hematocrit, lower baseline eGFR, lower calcium, higher phosphate, higher baPWV levels, and higher percentages of having received diuretics and ESAs. Table 5 shows a Cox proportional hazards regression analysis for progression to commencement of dialysis or death. The univariate regression analysis shows that the hazard ratio (HR) of the baPWV was 1.001 (95% confidence interval [CI], 1.000 to 1.001; P ϭ 0.004). In addition, other variables including the presence of cerebrovascular disease, decreased serum albumin, decreased LDL-cholesterol, decreased hematocrit, decreased baseline eGFR, decreased calcium, increased phosphate, increased log PTH level, no use of ACEI and/or ARB therapy, and the use of ESAs were associated with a significant increase in progression to commencement of dialysis or death. In the multivariate forward analysis, the baPWV (HR, 1.001; 95% CI, 1.000 to 1.001; P ϭ 0.001) and serum phosphate level (HR, 1.883; 95% CI, 1.183 to 2.997; P ϭ 0.008) were positively associated with and baseline eGFR (HR, 0.918; 95% CI, 0.862 to 0.977; P ϭ 0.007) was negatively associated with progression to commencement of dialysis or death. In addition, using baPWV as a categorical variable (baPWV above versus below the median of 1964 cm/s), we found the baPWV above the median was strongly associated with progression to commencement of dialysis or death (HR, 5.107; 95% CI, 1.527 to 17.086; P ϭ 0.008; Figure 3 ).
Discussion
In this study, we evaluated the influence of baPWV, a marker of arterial stiffness, on the decline in renal function and the risk of progression to a composite of commencing dialysis or death in a cohort of patient with moderate to advanced CKD. We found that baPWV was independently associated with renal function decline and progression to commencing dialysis or death. Other factors including hypertension, lower eGFR level, and higher phosphate level were also associated with renal function progression.
Previous studies have shown that a decreased eGFR was strongly correlated with increased arterial stiffness in CKD patients (5-7). However, those results were cross-sectional studies, and arterial stiffness was not able to predict the renal function progression. Recently, three longitudinal studies using different measurement methods of arterial stiffness showed increased arterial stiffness was an independent predictor for renal function progression in patients with CKD (10 -12). Takenaka et al. (12) studied the relationship between the augmentation index and the rate of decline in annual creatinine clearance in 41 nondiabetic CKD patients with a baseline creatinine clearance level of 52.4 ml/min and found higher basal augmentation index assessed on the radial artery waveform resulted in a greater annular creatinine clearance decrement. Taal et al. longitudinal relationship between change in renal function and the marker of aortic stiffness and found aortic PWV was independently associated with the rate of renal function decline in 120 CKD stage 3 and 4 patients with a baseline eGFR level of 32 ml/min per 1.73 m 2 . They also found aortic stiffness was associated with reaching combined end points of commencing of dialysis or Ն25% decline in eGFR. Although our measurement method was different from theirs, we also showed the significant association between baPWV with renal function progression, including a rapid eGFR decline and an increased risk for progression to commencing dialysis or death in 145 CKD stage 3 to 5 patients with a baseline eGFR level of 29.9 ml/min per 1.73 m 2 . Although the exact mechanisms for this association are currently unknown, it is possible that increased arterial stiffness results in greater transmission of elevated systemic BP to the glomerular capillaries, thereby exacerbating glomerular hypertension, a major determinant of progressive renal damage (22, 23) .
Although there were several parameters using in the assessment of arterial stiffness, the gold standard of noninvasive arterial stiffness measurement is carotid-femoral PWV (24) . The carotid-femoral PWV directly reflects aortic PWV (25, 26) . In contrast, baPWV reflects a composite of several arterial segments, some of which are prone to arteriosclerosis alone (brachial and distal arteries) and some to both atherosclerosis and arteriosclerosis (aorta and femoral arteries). Therefore, baPWV may not be as reliable as carotid-femoral PWV in reflecting aortic PWV. However, Tanaka et al. (27) compared carotid-femoral PWV and baPWV in 2287 patients and found a strong correlation between them (r ϭ 0.73, P Ͻ 0.001). These two parameters also exhibited similar extent of associations with cardiovascular disease risk factors and clinical events (27) . In addition, Yamashina et al. (15) compared aortic PWV derived from an invasive method and baPWV in 41 patients and showed a strong correlation between them (r ϭ 0.87, P Ͻ 0.01). Therefore, it is reasonable to use baPWV as a marker of arterial stiffness. In this study, we further confirmed that increased baPWV was a risk factor for renal function decline and progression to dialysis or death in CKD patients.
A high phosphate level was reported to be an independent risk factor for rapid renal function decline and increased mortality (28). Kasiske et al. (29) showed that a high protein diet may increase phosphate intake and ac- celerate renal function decline. Furthermore, a high plasma phosphate concentration may lead to the deposition of calcium phosphate crystals in either the mitochondria of tubular cells or renal interstitium, thereby causing cell damage and mitogenesis of fibroblasts, resulting in progressive loss of renal function (30) . Similarly, our study also showed that increased phosphate level was associated with progression to commencement of dialysis or death in patients with CKD.
ACEIs and ARBs have been shown to reduce neointimal proliferation and vascular inflammation (31) . In this study, the use of ACEIs and/or ARBs was associated with a significant decrease in progression to initiation of dialysis or death in univariate analysis. However, the use of ACEIs and/or ARBs was not significantly associated with the combined endpoint after multivariate Cox regression analysis. Thus, treatment with ACEIs and/or ARBs was not a major determinant of the combined endpoint in this study.
There were several limitations to this study. The baPWV was only measured at enrollment, and thus, we could not longitudinally assess the relationship between changes in arterial stiffness and kidney function. In addition, the number and interval of serum creatinine measurements for making the eGFR slope varied in each patient and thus the calculation of eGFR slope was not uniform in every subject. However, to decrease the chance of an unreliable estimation of eGFR slope, we excluded 13 patients with less than three eGFR measurements during the follow-up period, and 4 patients died and 7 patients started dialysis therapy within 30 days after enrollment. Finally, because eGFR tends to be less accurate in subjects with normal renal function than in those with CKD (32) and the reason of renal function decline in patients with normal renal function may be related to their primary diseases, i.e., glomerulonephritis or diabetic nephropathy, our results may be unable to apply in the patients with normal renal function.
In conclusion, our results showed that baPWV, a marker of arterial stiffness, has an independent association with renal function decline and progression to commencing dialysis or death in patients with moderate to advanced CKD. Screening CKD patients by means of baPWV may help identify a high-risk group of rapid renal function progression and progression to commencing dialysis or death. 
